OncoCyte

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Burning Rock Biotech

Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing agreement with China-based Burning Rock Biotech Ltd. to bring OncoCyte's DetermaRX test for early-stage lung cancer patients to China.

OncoCyte's stock soars after licensing deal with China-based company, days after insiders acquired shares

IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to present at the 13th Annual LD Micro Main Event Conference.

Oncocyte to Present at the 15th Annual LD Micro Main Event

Physician researchers from Yale Cancer Center and University of California San Francisco (UCSF) to present on test performance in immunotherapy and chemotherapy selection Physician researchers from Yale Cancer Center and University of California San Francisco (UCSF) to present on test performance in immunotherapy and chemotherapy selection

Oncocyte Corporation Hosting Key Opinion Leader Call on Proprietary Molecular Tests for Cancer Treatment Selection

Jaguar Health

Jaguar Health (NASDAQ: JAGX) shares are trading higher on Monday after the company announced its plans to develop and commercialize its Crofelemer. Jaguar Health is a commercial-stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products.

Why Jaguar Health And OncoCyte Are Trading Higher Today

IRVINE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming Piper Sandler Virtual Healthcare Conference on Tuesday, December 1, 2020.

Oncocyte to Participate at 32nd Annual Piper Sandler Virtual Healthcare Conference

Data demonstrate that DetermaIO™  can be run successfully using limited tissue from small biopsy specimens , overcoming the significant challenge s associated with tissue availability for molecular testing

Oncocyte Presents New Data on Its DetermaIO™ Test at Association for Molecular Pathology (AMP) 2020 Conference

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q3 2020 Results - Earnings Call Transcript

Data show DetermaIO™ may help to select effective therapeutic options for immune checkpoint inhibitor (ICI) resistant patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) Data show DetermaIO™ may help to select effective therapeutic options for immune checkpoint inhibitor (ICI) resistant patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC)

Oncocyte to Present DetermaIO™ Test Data at the 2020 Society for Immunotherapy of Cancer (SITC) Conference

Oncocyte named in Top 5 as one of Orange County's Best Places to Work in 2020 in its first year Oncocyte named in Top 5 as one of Orange County's Best Places to Work in 2020 in its first year

Oncocyte Named One of the 2020 Best Places to Work in Orange County in Its First Year in Irvine, CA

Testing volume for DetermaRx more than doubled in Q3 202 0

Oncocyte Announces Third Quarter Growth of DetermaRx™ Physician Adoption and Testing Volume

Chronix’s blood - based test monitors the effectiveness of immunotherapy drugs in clinical trials , and potentially in patients receiving immunotherapy treatment

Oncocyte Agrees to Enter Licensing and Collaboration Agreement with Chronix Biomedical

IRVINE, Calif., Sept.  14, 2020  (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that Ronald Andrews, Chief Executive Officer, and Doug Ross, MD., Ph.D., Chief Medical Officer, will participate at the upcoming Lake Street Capital Markets 4th Annual Best Ideas Growth Conference, being held virtually on September 17, 2020.

Oncocyte to Participate at the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference

Pricing in line with comparable high-value molecular tests for oncology indications

Oncocyte Receives Final Pricing Decision for DetermaRx™ Molecular Test for Lung Cancer from Centers for Medicare and Medicaid Services

Collaboration establishes an integrated platform for precision medicine clinical trials, combining Oncocyte’s proprietary molecular tests and fully certified pharma services lab with GRN’s nationwide hospital consortium of 150 hospitals, clinical trial networks and real-world evidence data technology to establish an integrated precision medicine trial platform

Oncocyte and the Guardian Research Network® Announce Strategic Alliance

IRVINE, Calif., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced the appointment of Jennifer Levin Carter, MD, MPH, MBA to its Board of Directors.

Oncocyte Announces Addition of Experienced Healthcare Executive, Jennifer Carter, MD, MPH, MBA to Board of Directors

IRVINE, Calif., Aug.  13, 2020  (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.

Oncocyte to Participate at Needham Virtual Cancer Diagnostics Conference

Event to feature Dr. Naoto Ueno, study investigator and medical oncologist at the University of Texas MD Anderson Cancer Center

Oncocyte to Hold KOL Webinar Highlighting Clinical Data on Its DetermaIO™ Test for Immunotherapy Response Prediction

Oncocyte Corporation's (OCX) CEO Ronnie Andrews on Q2 2020 Results - Earnings Call Transcript

 Secured National Medicare Reimbursement for DetermaRx™ Starting August 2020 with Final Medicare LCD from Palmetto GBA and Noridian Healthcare Solutions

Oncocyte Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Event to feature renowned lung cancer experts Dr. David Gandara and Dr. Johannes Kratz

Oncocyte to Hold KOL Webinar Showcasing New Data and Real World Usage of DetermaRx™

IRVINE, Calif., July  20, 2020  (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will release its financial and operating results for the second quarter ended June 30, 2020, on Wednesday, July 29, 2020, after the close of the U.S. financial markets. The Company will host a conference call on Wednesday, July 29, 2020, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Oncocyte to Report Second Quarter 2020 Financial Results on Wednesday, July 29

Noridian's decision aligns with Palmetto GBA's final LCD for the test announced in April

Oncocyte Announces Final Local Coverage Determination from Noridian Healthcare Solutions for DetermaRx™, Securing National Medicare Payment for the Test Starting August 2020

Oncocyte continues global expansion of DetermaRx with its second international agreement this year Oncocyte continues global expansion of DetermaRx with its second international agreement this year

Oncocyte Announces Distribution Agreement with ProGenetics Ltd, Expanding Commercial Availability of DetermaRx™ to Israel

Testing volume for DetermaRx™ doubled from Q1 2020 to Q2 2020 despite challenging COVID-19 macroenvironment Testing volume for DetermaRx™ doubled from Q1 2020 to Q2 2020 despite challenging COVID-19 macroenvironment

Oncocyte Provides an Update on the Rapid Growth of DetermaRx™ Physician Adoption and Testing Volume

Oncocyte: Despite The Bad Result Of DetermaDX The Comany Still Has Bullish Potential

News for OncoCyte Stock (OCX)